Benign Prostatic Hyperplasia - BPH Treatment - Enlarged Prostate Treatment
Benign Prostatic Hyperplasia Treatment (BPH Treatment) Overview
Urologix, Inc., based in Minneapolis, Minnesota develops, manufactures and markets minimally invasive urological treatment products. Urologix has developed and offers non-surgical, catheter-based treatments that use proprietary microwave technology for the treatment of benign prostatic hyperplasia (BPH), a condition that affects more than 23 million men worldwide. Urologix is a leader in less invasive technology for the BPH treatment, with more than 225,0001 patients treated to date.
Urologix' patented Cooled ThermoTherapy™ technology is creating effective2 treatment options for a wide range of patients with BPH. Cooled ThermoTherapy enlarged prostate treatment delivers precisely targeted microwave energy that heats and destroys enlarged prostatic tissue while unique cooling mechanisms protect surrounding healthy tissue. This benign prostatic hyperplasia treatment also enhances patient comfort.
Urologix' stock is traded on NASDAQ under the symbol ULGX. The company is focused on product development and expansion of its fast-growing mobile BPH treatment services.
1Data on file at Urologix, Inc.
2Miller, Paul D., et al, Cooled ThermoTherapy for the Treatment of Benign Prostatic Hyperplasia: Durability of Results Obtained with the Targis System, Urology, Vol. 61, No. 6, June 2003.
Milestones
1991
- Urologix® is founded to develop manufacture and market medical devices for the treatment of urological disorders
1997
- Urologix' first product, the Targis® Cooled TUMT System, is approved by the FDA as a safe, durable, minimally invasive urological treatment alternative to drugs and surgery for the treatment of BPH
1999
- Cruise software update including automated urethral feedback introduced
2000
- Urologix purchases the Prostatron® Cooled TUMT System
- Cruise II software update with enhanced rectal temperature feedback preventing unnecessary system shut downs introduced
- Shorter treatment time (28.5 minutes) approved
2002
- Targis Microwave Catheter [Short] introduced
2003
- Targis Microwave Catheter [Long] introduced
- Cooled ThermoCath® (CTC) [Standard] Microwave Catheter receives FDA approval
- Rectal Thermal Unit Plus offered
2005
- Urologix acquires three regional mobile BPH treatment service providers and launched its Urologix Mobile™ Service
- Cooled ThermoCath (CTC) [Long] Microwave Catheter receives FDA approval
2006
- The CoolWave® Control Unit enabling urologists to further customize benign prostatic hyperplasia treatment (BPH treatment) options for individual patients, is approved by the FDA and released to the marketplace
2007
- Developed software upgrade for Targis System
- Began CTC Advance™ Microwave Catheter* development
2008
- CTC Advance™ Microwave Catheter receives FDA approval
- 5 Year results for Cooled ThermoTherapy™ presented at AUA, Continuing Results of a Multi-Center Trial of a New Generation Cooled TUMT for BPH
Board of Directors
Stryker Warren, Jr. |
Chief Executive Officer |
Mitchell Dann |
Chairman of the Board |
Sidney W. Emery, Jr. |
Retired Chairman and Chief Executive Officer |
Guy C. Jackson |
Retired Partner |
Christopher R. Barys |
|
Patrick D. Spangler |
Operating Partner / CFO Advisor |
Leadership Team
Stryker Warren, Jr. |
Chief Executive Officer |
Gregory J. Fluet |
Executive Vice President & Chief Operating Officer |
Brian Smrdel |
Chief Financial Officer |
Ralph Cardinal |
Vice President, Research & Development |
Jennifer Willner |
Director of Regulatory & Quality |
Silke Kuralle |
Senior Marketing Manager |
Charles Lehman |
Director of Operations |
|
|
Media Room
Welcome to Urologix’ Media Room, the resource for up-to-date Cooled ThermoTherapy™ branded press releases, high-resolution images and current fact sheets. If you would like to download these materials, we ask that you fill out a brief form.
Urologix Fact Sheet
Urologix Mobile Fact Sheet
Cooled ThermoTherapy Fact Sheet
Cooled ThermoTherapy FAQs
